SCHEMBL987389

SCHEMBL987389

O=C(O)c1cc(C(F)(F)F)ccc1-n1ccc2cc(Cl)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.41
MPO P05164 1/20 0.41
LIPG Q9Y5X9 8/20 0.40
CCR2 P41597 2/20 0.40
MYC P01106 1/20 0.40
NR4A1 P22736 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MARS1 P56192 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM1A O60341 1/20 0.38
LPL P06858 3/20 0.38
OXER1 Q8TDS5 1/20 0.38
ACLY P53396 1/20 0.38
LIPC P11150 1/20 0.38
ROCK2 O75116 1/20 0.38
PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12584626 0.87 MYC (0.51) CCR2MYCNR4A1KDM4EALDH1A1
SCHEMBL12585814 0.82 PTGER4 (0.51) HPGD
SCHEMBL1271471 0.79 TDP1 (0.48) CCR2MYCNR4A1ALDH1A1HPGD
SCHEMBL987880 0.77 P2RX3 (0.36)
SCHEMBL12584649 0.76 GAA (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL15712830 0.71 MPO (0.66) GRIK1MPOHPGDMEN1KMT2A
SCHEMBL122436 0.69 MGLL (0.57) HPGDROCK2PIM1PIM3
SCHEMBL12585817 0.68 PTGER4 (0.50) ALDH1A1HPGD
SCHEMBL12135332 0.68 SETD7 (0.51) NR4A1HPGDHSD17B10MEN1KMT2A
SCHEMBL78221 0.67 MRGPRX4 (0.61) LIPGKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
CN-102026961-A Amide compound ASTELLAS PHARMA INC 2011-04-20 CN disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed
WO-2009139373-A1 AMIDE COMPOUND アステラス製薬株式会社 (JP) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 GRIK1 1137/4885MPO 4060/4885LIPG 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.